Welcome to our dedicated page for Innocan Pharma SEC filings (Ticker: INNPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to Innocan Pharma Corporation (INNPF) regulatory filings as they become available through official channels such as the U.S. Securities and Exchange Commission. While no SEC filings are listed in the current data, the company has stated that additional details regarding an anticipated NYSE American listing and a concurrent offering of its securities would be provided through its filings with the SEC and SEDAR+.
Stock Titan organizes Innocan-related filings by form type, allowing users to review annual and quarterly reports when they are filed, as well as current reports and other disclosure documents. For a healthcare company in the drug manufacturers – specialty and generic industry, these filings can include information on research and development activities, regulatory interactions, risk factors, and capital markets transactions, as disclosed by the company.
As filings such as registration statements or periodic reports become available, Stock Titan’s platform can pair them with AI-powered summaries that explain key sections in accessible language. Users can use these tools to better understand complex disclosure topics, such as drug development programs, wellness product activities, and the terms of offerings or exchange listings described by Innocan in its public communications.
When insider transaction reports or other ownership-related documents are filed, they can also be accessed here, helping users track changes in reported holdings. All information is drawn from official filing sources, with real-time updates from EDGAR where applicable, and presented alongside AI-generated explanations to help readers interpret the technical and regulatory content.
Innocan Pharma Corporation is offering up to 3,750,000 Units (each Unit: one common share and one warrant) and up to 3,750,000 pre-funded Units in an initial public offering priced between $5.00 and $6.00 per Unit. The warrants have an exercise price of $6.875 and expire five years from issuance. The prospectus gives effect to a 65-for-1 reverse share split and states common shares to be outstanding after this offering of 8,248,772 (or 8,811,272 if the underwriter exercises the over-allotment in full). Based on a $5.50 midpoint, net proceeds to the company are expected to be approximately $17.98 million (about $20.82 million with full over-allotment). The offering includes an option to purchase up to 562,500 additional common shares and/or warrants to cover over-allotments. Use of proceeds highlights R&D for human and veterinary LPT-CBD programs, manufacturing scale-up, and U.S. marketing.